LANGaware has announced the completion of its new funding round with the aim of revolutionizing the early detection of neurodegenerative diseases. Strategic investors in the healthcare industry led the investment round, which was also attended by existing investor Metavallon VC.
LANGaware, founded by Vasiliki Rentoumi, a researcher in the field of Natural Language Processing and Computational Linguistics, uses artificial intelligence to predict neurodegenerative and psychiatric conditions, such as Alzheimer’s disease and depression, through the detection and monitoring of digital biomarkers based on language, voice and speech. The technology behind the platform, now patented through the United States Patent and Trademark Office (USPTO), is the product of years of research and has already been incorporated into a number of recognized clinics and aged care units in the United States and Greece.
The LANGaware platform’s solution aims to help healthcare providers promote research, improve care, and provide personalized support to people facing such conditions. LANGaware’s clients include clinics, hospitals, aged care units and pharmaceutical companies.These clients are now able to identify, promptly, people at high risk or diagnosed with Alzheimer’s disease or other neurodegenerative and psychiatric diseases and to monitor the effectiveness of the treatment provided.
“The battle with dementia requires all our momentum. That’s why we have developed a “virtual expert” who helps in the early diagnosis and monitoring of the disease with the aim of offering patients a better quality of life. Our solution provides primary care physicians with an accurate tool for diagnosis, pharmaceutical companies with a more effective patient triage tool for their clinical trials, and finallypatients have a remote assessment and monitoring of the disease from the comfort of their own home.”, said LangaAware CEO Vasiliki Rentoumi.
“This revolutionary technology is on the way to change the face of both neurodegenerative and psychiatric conditions, providing faster intervention and effective monitoring, thus enabling earlier treatments. LANGaware helps to redefine the good quality of life, making the diagnosis of such ailments easy and affordable. This funding will strengthen our mission and accelerate our growth.”, stated Hollie Kemp, Business Administrator of LangaAware.
“At Langaware we find both an excellent company to invest in and the inspiration for how technology and entrepreneurs can create a better life for the people around us.We are excited to support such a powerful digital diagnostic platform towards solving these ever-increasing challenges, with the already huge market it serves, as well as with its potential to expand in order to address a multitude of neurodegenerative and psychiatric conditions, a sign of value for both our investors and the over a billion patients who can benefit.”, commented Alexandra Choli, partner of Metavallon VC.